Abstract

Is It Good or Bad to Find a <i>BRAF</i> Mutation?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Analysis of KRAS and BRAF mutant colorectal cancers in a multiracial population.
Jared David Acoba ... Lambert T Leong
Journal of Clinical Oncology | VOL. 30
Jared David Acoba, et. al.Jared David Acoba ... Lambert T Leong
20 May 2012
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Sapna P Patel ... Michael A Davies
Cancer | VOL. 119
Sapna P Patel, et. al.Sapna P Patel ... Michael A Davies
12 Sep 2012
1147 - BRAF Mutations Are Frequent in Malignant Melanoma in Israeli Population and Predicts Poor Response to Biochemotherapy
I Lazarev ... S Ariad
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 23
I Lazarev, et. al.I Lazarev ... S Ariad
01 Sep 2012
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
Kaori Sakaizawa ... Hisashi Uhara
Journal of Dermatological Science | VOL. 80
Kaori Sakaizawa, et. al.Kaori Sakaizawa ... Hisashi Uhara
26 Jul 2015
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.
Alain P Algazi ... Suzanne Dufault
Journal of Clinical Oncology | VOL. 42
Alain P Algazi, et. al.Alain P Algazi ... Suzanne Dufault
01 Jul 2024
Erratum: Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial.
-
Journal of Clinical Oncology | VOL. 42
--
01 Jul 2024
FDA Approval Summary: Eflornithine for High-Risk Neuroblastoma Following Prior Multiagent, Multimodality Therapy.
Elizabeth S Duke ... Nicole Drezner
Journal of Clinical Oncology | VOL. -
Elizabeth S Duke, et. al.Elizabeth S Duke ... Nicole Drezner
25 Jun 2024
Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability.
Natansh D Modi ... Ashley M Hopkins
Journal of Clinical Oncology | VOL. -
Natansh D Modi, et. al.Natansh D Modi ... Ashley M Hopkins
25 Jun 2024
View more papers